Nightstar Therapeutics
Biogen is a global biotechnology company focused on neuroscience, immunology and rare disease research. The company conducts discovery and clinical development across multiple therapeutic modalities (including monoclonal antibodies, antisense oligonucleotides, gene therapy and small molecules), operates large-scale biologics and oligonucleotide manufacturing capacity, runs global clinical trials and early-access programs, provides patient resources and support initiatives, and reports on environmental and sustainability performance.
Industries
Nr. of Employees
small (1-50)
Services
Design and operational delivery of clinical studies, investigator engagement, trial recruitment platforms and trial transparency practices.
Commercial and clinical manufacturing capabilities including fed-batch cell culture, protein purification, oligonucleotide manufacturing, parenteral filling and oral solid dose production.
Evaluation and administration of early access requests for investigational drugs and provision of medical information and country-specific support.
Integrated preclinical-to-clinical development support for investigational therapies across modalities and disease areas, including Phase 1–3 clinical development planning.
Design and operational delivery of clinical studies, investigator engagement, trial recruitment platforms and trial transparency practices.
Commercial and clinical manufacturing capabilities including fed-batch cell culture, protein purification, oligonucleotide manufacturing, parenteral filling and oral solid dose production.
Evaluation and administration of early access requests for investigational drugs and provision of medical information and country-specific support.
Integrated preclinical-to-clinical development support for investigational therapies across modalities and disease areas, including Phase 1–3 clinical development planning.
Expertise Areas
- Clinical trial management and operations
- Biologics and oligonucleotide manufacturing
- Antisense oligonucleotide (ASO) development
- Neurology and neurodegeneration research (including Alzheimer’s disease)
Key Technologies
- Antisense oligonucleotides (ASOs)
- Gene therapy
- Monoclonal antibodies
- Small-molecule drug discovery (including kinase inhibitors)